Francis Anna, Trnka Peter, McTaggart Steven J
Child and Adolescent Renal Service, Lady Cilento Children's Hospital, Brisbane, Queensland, Australia; and.
School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2041-2046. doi: 10.2215/CJN.03060316. Epub 2016 Oct 20.
FSGS can recur after kidney transplantation and is associated with poor graft outcomes. We aimed to assess the incidence of FSGS recurrence post-transplant and determine the effect of graft source on recurrence and graft survival in patients with biopsy-proven FSGS.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using the Australian and New Zealand Dialysis and Transplant Registry, we assessed incidence of FSGS, the influence of donor type on the risk of FSGS recurrence, and graft loss in recipients with ESRD caused by primary FSGS using Kaplan-Meier and logistic regression analyses.
Between 1992 and 2011, 736 first kidney transplants were performed in 666 adults and 70 children (≤20 years old) with biopsy-proven primary FSGS. FSGS recurred in 76 (10.3%) patients. Younger age (P<0.001), nonwhite ethnicity (P=0.02), and having a live donor (P=0.02) were independent risk factors associated with recurrence. Median graft survival was significantly better for live donor compared with deceased donor grafts (14.8 versus 12.1 years; P<0.01). Disease recurrence predicted poor graft outcomes, with 52% (95% confidence interval, 40% to 63%) 5-year graft survival in the recurrence group compared with 83% (95% confidence interval, 79% to 86%) in the group without recurrent disease (P<0.001).
FSGS recurrence after kidney transplantation was more common in live donor kidneys. Despite this, graft survival in live donor recipients was significantly better for both children and adults with FSGS. We propose that live donor transplantation should not be avoided in patients with FSGS.
局灶节段性肾小球硬化症(FSGS)在肾移植后可能复发,并与移植肾预后不良相关。我们旨在评估移植后FSGS复发的发生率,并确定移植物来源对经活检证实为FSGS患者复发及移植肾存活的影响。
设计、场所、参与者及测量方法:利用澳大利亚和新西兰透析与移植登记处的数据,我们采用Kaplan-Meier和逻辑回归分析,评估了FSGS的发生率、供体类型对FSGS复发风险的影响,以及原发性FSGS导致的终末期肾病(ESRD)受者的移植肾丢失情况。
1992年至2011年期间,对666名成人和70名儿童(≤20岁)进行了736例首次肾移植,这些患者均经活检证实为原发性FSGS。76例(10.3%)患者出现FSGS复发。年龄较小(P<0.001)、非白人种族(P=0.02)以及接受活体供肾(P=0.02)是与复发相关的独立危险因素。活体供肾移植肾的中位存活时间显著长于尸体供肾移植肾(14.8年对12.1年;P<0.01)。疾病复发预示着移植肾预后不良,复发组5年移植肾存活率为52%(95%置信区间,40%至63%),而无疾病复发组为83%(95%置信区间,79%至86%)(P<0.001)。
肾移植后FSGS复发在活体供肾中更为常见。尽管如此,FSGS患儿和成人接受活体供肾移植后的移植肾存活率均显著更高。我们建议,FSGS患者不应避免接受活体供肾移植。